Public Employees Retirement System of Ohio Makes New Investment in OmniAb, Inc. $OABI

Public Employees Retirement System of Ohio acquired a new position in shares of OmniAb, Inc. (NASDAQ:OABI) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 96,361 shares of the company’s stock, valued at approximately $168,000. Public Employees Retirement System of Ohio owned about 0.08% of OmniAb at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Murchinson Ltd. increased its stake in shares of OmniAb by 0.8% in the 1st quarter. Murchinson Ltd. now owns 1,007,810 shares of the company’s stock valued at $2,419,000 after acquiring an additional 7,810 shares during the last quarter. Squarepoint Ops LLC increased its stake in shares of OmniAb by 33.3% in the 4th quarter. Squarepoint Ops LLC now owns 39,264 shares of the company’s stock valued at $139,000 after acquiring an additional 9,809 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of OmniAb in the 1st quarter valued at about $25,000. Cerity Partners LLC bought a new stake in shares of OmniAb in the 1st quarter valued at about $26,000. Finally, PNC Financial Services Group Inc. increased its stake in shares of OmniAb by 279.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 16,276 shares of the company’s stock valued at $39,000 after acquiring an additional 11,986 shares during the last quarter. 72.08% of the stock is owned by institutional investors.

OmniAb Stock Performance

NASDAQ OABI opened at $1.68 on Tuesday. The stock has a market cap of $241.85 million, a price-to-earnings ratio of -2.80 and a beta of 0.15. OmniAb, Inc. has a 52-week low of $1.22 and a 52-week high of $4.87. The business has a 50 day simple moving average of $1.74 and a 200 day simple moving average of $1.78.

OmniAb (NASDAQ:OABI) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The business had revenue of $3.90 million for the quarter, compared to the consensus estimate of $5.33 million. OmniAb had a negative return on equity of 22.79% and a negative net margin of 275.83%. On average, analysts predict that OmniAb, Inc. will post -0.61 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OmniAb in a research note on Saturday, September 27th. Royal Bank Of Canada lowered their price target on OmniAb from $4.00 to $3.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $6.67.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.